Longitudinal analysis of peripheral immune cells in patients with multiple sclerosis treated with anti-CD20 therapy

被引:0
作者
Waede, Mie [1 ,2 ,3 ]
Voss, Lasse F. [4 ]
Kingo, Christina [1 ,2 ,3 ]
Moeller, Jesper B. [3 ,5 ]
Elkjaer, Maria L. [1 ,2 ,3 ,6 ]
Illes, Zsolt [1 ,2 ,3 ,7 ]
机构
[1] Odense Univ Hosp, Dept Neurol, Odense, Denmark
[2] Univ Southern Denmark, Dept Clin Res, Odense, Denmark
[3] Univ Southern Denmark, Dept Mol Med, Odense, Denmark
[4] Tech Univ Denmark, Dept Hlth Technol, Sect Expt & Translat Immunol, Lyngby, Denmark
[5] Univ Southern Denmark, Danish Inst Adv Study, Odense, Denmark
[6] Univ Hamburg, Inst Computat Syst Biol, Hamburg, Germany
[7] Univ Southern Denmark, BRIDGE Brain Res Interdisciplinary Guided Excellen, Odense, Denmark
来源
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY | 2024年 / 11卷 / 10期
关键词
NATURAL-KILLER-CELLS; T-CELLS; CHEMOKINE RECEPTORS; NK CELLS; CEREBROSPINAL-FLUID; ACTIVATION; EXPRESSION; RITUXIMAB; CD38; INFLAMMATION;
D O I
10.1002/acn3.52182
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: Anti-CD20 therapy is a highly effective treatment for multiple scle-rosis (MS). In this study, we investigated MS-related changes in peripheralblood mononuclear cell (PBMC) subsets compared to healthy controls and lon-gitudinal changes related to the treatment.Methods: Multicolor spectral flowcytometry analysis was performed on 78 samples to characterize disease- andtreatment-related PBMC clusters. Blood samples from MS patients were col-lected at baseline and up to 8 months post-treatment, with three collectionpoints after treatment initiation. Unsupervised clustering tools and manual gat-ing were applied to identify subclusters of interest and quantify changes. Results: B cells were depleted from the periphery after anti-CD20 treatment asexpected, and we observed an isolated acute, transitory drop in the proportionof natural killer (NK) and NKT cells among the main populations of PBMC(P=0.03,P=0.004). Major affected PBMC subpopulations were cytotoxicimmune cells (NK, NKT, and CD8(+)T cells), and we observed a higher propor-tion of cytotoxic cells with reduced brain-homing ability and a higher regula-tory function as a long-term anti-CD20-related effect. Additionally, anti-CD20therapy altered distributions of memory CD8(+)T cells and reduced exhaustionmarkers in both CD4(+)and CD8(+)T cells.Interpretation: The findings of thisstudy elucidate phenotypic clusters of NK and CD8(+)T cells, which have previ-ously been underexplored in the context of anti-CD20 therapy. Phenotypicmodifications towards a more regulatory and controlled phenotype suggest thatthese subpopulations may play a critical and previously unrecognized role inmediating the therapeutic efficacy of anti-CD20 treatments.
引用
收藏
页码:2657 / 2672
页数:16
相关论文
共 50 条
[21]   Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis [J].
Sellebjerg, Finn ;
Blinkenberg, Morten ;
Sorensen, Per Soelberg .
CNS DRUGS, 2020, 34 (03) :269-280
[22]   The Evolution of Anti-CD20 Treatment for Multiple Sclerosis: Optimization of Antibody Characteristics and Function [J].
Cree, Bruce A. C. ;
Berger, Joseph R. ;
Greenberg, Benjamin .
CNS DRUGS, 2025, :545-564
[23]   Anti-CD20 therapy corrects a CD8 regulatory T cell deficit in multiple sclerosis [J].
Howlett-Prieto, Quentin ;
Feng, Xuan ;
Kramer, John F. ;
Kramer, Kevin J. ;
Houston, Timothy W. ;
Reder, Anthony T. .
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (14) :2170-2179
[24]   Anti-CD20 monoclonal antibodies in multiple sclerosis: Rethinking the current treatment strategy [J].
Freeman, S. A. ;
Zephir, H. .
REVUE NEUROLOGIQUE, 2024, 180 (10) :1047-1058
[25]   Anti-CD20 monoclonal antibody therapy in multiple myeloma [J].
Kapoor, Prashant ;
Greipp, Patricia T. ;
Morice, William G. ;
Rajkumar, S. Vincent ;
Witzig, Thomas E. ;
Greipp, Philip R. .
BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 (02) :135-148
[26]   Comparison of the Efficacy and Safety of Anti-CD20 B Cells Depleting Drugs in Multiple Sclerosis [J].
Cotchett, Kelly R. ;
Dittel, Bonnie N. ;
Obeidat, Ahmed Z. .
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 49
[27]   Hypogammaglobulinemia and severe infections in Multiple Sclerosis patients on anti-CD20 agents: A multicentre study [J].
Smolik, K. ;
Camilli, F. ;
Panzera, I. ;
Fiore, A. ;
Franceschini, A. ;
Foschi, M. ;
Surcinelli, A. ;
Pesci, I. ;
Ferri, C. ;
Bazzurri, V. ;
Mancinelli, L. ;
Zini, C. ;
Simone, A. M. ;
Lugaresi, A. ;
Falzone, F. ;
Granella, F. ;
Piscaglia, M. G. ;
Guareschi, A. ;
Baldi, E. ;
Immovilli, P. ;
Montepietra, S. ;
Santangelo, M. ;
Poma, N. ;
Cardi, M. ;
De Napoli, G. ;
Vitetta, F. ;
Ferraro, D. .
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2025, 93
[28]   Anti-CD20 Disrupts Meningeal B-Cell Aggregates in a Model of Secondary Progressive Multiple Sclerosis [J].
Roodselaar, Jay ;
Zhou, Yifan ;
Leppert, David ;
Hauser, Anja E. ;
Urich, Eduard ;
Anthony, Daniel C. .
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2021, 8 (03)
[29]   Anti-CD20 therapy and pauci-immune crescentic glomerulonephritis [J].
Shu, Kai-Hsiang ;
Chiang, Wen-Chih ;
Chiu, Yen-Ling .
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2017, 116 (04) :215-216
[30]   Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment [J].
Delgado, Silvia R. ;
Faissner, Simon ;
Linker, Ralf A. ;
Rammohan, Kottil .
JOURNAL OF NEUROLOGY, 2024, 271 (04) :1515-1535